Abstract
Progressive hyperpigmentation of the skin, increased concentrations of plasma ACTH, and occurrence of a pituitary tumor after bilateral adrenalectomy in patients with Cushing's disease were first described by Nelson et al. (1958) and by Salassa et al. (1959) .
Nelson's syndrome occurs in 10-35% of patients who have undergone total adrenalectomy for Cushing's disease (Moore et al., 1976 ; Cohen et al., 1978) . The mechanism of the occurrence of the pituitary tumor in these patients remains undetermined. Most patients with Cushing's disease appear to have an ACTH-secreting microadenoma in the pituitary (Tyrrell et al., 1978 ; Bigos et al., 1980 ; Kuwayama et al., 1981) which may lead to an increase in tumor growth following total adrenalectomy.
The primary structure of corticotropin-releasing factor (CRF) from ovine (o) hypothalami has been determined by Vale et al. (1981) . The native oCRF and its synthetic counterpart have been shown to be fully active in vitro as well as in vivo in stimulating ACTH release from the pituitary of animals (Vale et al., 1981 ; Rivier et al., 1982; Vale et al., 1983 ; Donald et al., 1983 ; Schulte et al., 1982) and humans (Grossman et al., 1982 ; Orth et al., 1983 ; Muller et al., 1982 ; Nakahara et al., 1983 ). The present study was designed to study the effect of synthetic oCRF on release of ACTH in a patient with Nelson's syndrome, and to investigate the effects of bromocriptine and cyproheptadine on basal and CRF-induced ACTH release. was normal. Administration of synthetic oCRF caused an exaggerated response (about a sixfold increase in plasma ACTH over the basal levels) compared to the responses to oCRF in normal subjects (Fig. 2) (Orth et al., 1973 ; Gewirtz and Yalow, 1974) . Thus, hypersecretion of ACTH in this case probably originates from the pituitary. Selective venous sampling of ACTH from the inferior petrosal sinus should provide a more reliable aid to differentiate these two entities (Findling et al., 1981 ; Tanaka et al., 1984) .
The endocrine features in this case also appear to be consistent with those of Nelson's syndrome ; the plasma ACTH response to LVP, the paradoxical response to LHRH and the suppressive effect of both bromocriptine and cyproheptadine are often found in some patients with Cushing's disease or Nelson's syndrome (Krieger et al., 1975 ; Krieger et al., 1976 ; Krieger et al., 1977 ; Lamberts et al., 1977 ; Lamberts et al., 1980; Pieters et al., 1982) . The failure of plasma ACTH response to insulin-induced hypoglycemia in this case would not be of any help in the diagnosis because various responses to hypoglycemic stress have been reported in Nelson's syndrome (Krieger and Luria, 1977 ; Imura et al., 1980) . oCRF is a potent secretagogue for ACTH release in human, and is a useful diagnostic tool in patients with hypothalamic-pituitaryadrenal disorders (Grossman et al., 1982 ; Muller et al., 1982 ; Nakahara et al., 1983) . The results of hyperresponsiveness of plasma ACTH to oCRF in our case (Fig. 2) are consistent with those reported by others (Muller et al., 1982 ; Nakahara et al., 1983) . Therefore, it is suggested that ACTH release from the pituitary tumor in Nelson's syndrome may not be autonomous but still regulated by hypothalamic CRF.
It has been reported that bromocriptine, a dopamine agonist, and cyproheptadine, a serotonin antagonist, are effective in reducing ACTH release, and thus could be used for treatment in some patients with Cushing's disease or Nelson's syndrome (Krieger et al., 1975 ; Krieger et al., 1976 ; Benker et al., 1976 ; Lamberts et al., 1977 ; Lamberts et 1980). The present study clearly shows a marked suppressive effect of both drugs on the basal ACTH release (Fig. 1) . Furthermore, short-term (3-week) treatment with either drug resulted in a marked reduction in basal and CRF-induced ACTH release (Fig. 3) . It seems unlikely that this effect may be due to spontaneous fluctuation in ACTH release or exogenous hydrocortisone because no significant variation in plasma ACTH was observed on the control day (Fig. 2) . The site(s) on which these drugs act remains undetermined.
Changes in neurotransmitters in the central nervous system, such as an increase in serotonin content and/or depletion of dopamine content may be involved in the pathogenesis of Cushing's disease (Krieger et al., 1975 ; Lamberts et al., 1977) ; modulation of the hypothalamic neurotransmitters by cyproheptadine or bromocriptine may cause a reduction in ACTH release, and thus lead to clinical remission in some patients with Cushing's disease and Nelson's syndrome.
Indeed, serotonin increases CRF secretion from rat hypothalamic fragments incubated in vitro (Jones & Hillhouse, 1977) , whereas serotonin itself has no effect on ACTH release from the pituitary (Lamberts et al., 1980 ; Gillies et al., 1980 ; Mashiter et al., 1980 , Ishibashi et al., 1981 . Cyproheptadine and bromocriptine both reduce ACTH release from pituitary adenomas causing Cushing's disease in vitro (Lamberts et al., 1980 ; Adams et al., 1981 ; Ishibashi et al., 1981 ; Suda et al., 1983) , suggesting a direct action of either drug at the pituitary level. The suppressive effect on both basal and CRF-induced ACTH release by cyproheptadine and bromocriptine in this case suggests that both drugs exert their effect directly on the pituitary rather than by reducing hypothalamic endogenous CRF.
The failure of the suppressive effect on basal and CRF-induced ACTH release after a longer period of treatment with cyproheptadine (18-week) may be in accordance with the fact that relapse occurs in patients with Cushing's disease even after a successful long-term treatment with this drug (Krieger, 1979) . This phenomenon may be accounted for by the refractory responsiveness of the drug after chronic treatment. However, the results of this study of a single patient do not make it possible to conclude that both cyproheptadine and bromocriptine are effective in treating Nelson's syndrome. Further study should be done on a wide range of patients with Nelson's syndrome.
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